Processa Pharmaceuticals, Inc.

Listed Company

PCSACIK 0001533743NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-13.56M

Total Assets

—

Equity

—

Shares Out

2.75M

Op. Cash Flow

$-11.39M

Business

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) small molecules and selected non-oncology assets. It offers modified versions of established oncology drugs—NGC-Cap (PCS6422 plus capecitabine), NGC-Gem (PCS3117), NGC-Iri (PCS11T)—alongside non-oncology candidates PCS12852 and PCS499. The company’s operations focus on drug development, regulatory science-driven trial design, licensing agreements and potential out-licensing or partnerships to advance programs. It conducts global clinical trials and relies on third-party contract manufacturing organizations and licensing partners for distribution and commercialization.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development expenses	8	7	6	11	7
General and administrative expenses	6	5	6	9	5
Operating Loss	−14	−12	−11	−28	−12
Other income	20,000	—	—	—	—
Unrealized gain on digital assets at fair value	295,180	—	—	—	—
Interest and dividend income, net	109,491	201,088	335,541	101,202	11,627
Net Operating Loss Before Income Tax Benefit	−14	−12	−11	−27	−12
Income Tax Benefit	—	—	—	—	530,611
Net Loss	−14	−12	−11	−27	−11
Net Loss Per Common Share - Basic	−10.36	−96.78	−8.48	−34.05	−0.75
Net Loss Per Common Share - Diluted	−10.36	−96.78	−8.48	−34.05	—
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic	1	122,438	1	805,477	15
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted	1	122,438	1	805,477	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	6	1	5	7	16
Prepaid expenses and other	133,919	687,829	926,300	2	2
Total Current Assets	6	2	6	8	18
Digital assets at fair value	1	—	—	—	—
Prepaid expenses	993,701	1	—	—	—
Equipment, net	3,812	5,016	2,554	—	—
Operating lease right-of-use assets, net	—	70,677	146,057	227,587	74,181
Total Assets	8	3	6	9	26
Current maturities of lease liability	—	73,020	83,649	—	—
Accounts payable	1	880,880	311,617	327,548	218,905
Accrued expenses	1	578,731	146,274	403,061	279,265
Total Current Liabilities	2	2	730,579	998,556	971,020
Non-current lease liability	—	487	66,905	—	—
Total Liabilities	2	2	797,484	1	978,405
Commitments and Contingencies	—	—	—	—	—
Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at December 31, 2025 or 2024	—	—	—	—	—
Common stock, par value $0.0001, 1,000,000,000 shares authorized; 2,572,114 issued and 2,571,914 outstanding at December 31, 2025 and 148,308 issued and 148,108 outstanding at December 31, 2024	257	15	129	80	1,571
Additional paid-in capital	107	89	81	72	62
Treasury stock, 200 shares at cost	−300,000	−300,000	−300,000	−300,000	—
Accumulated deficit	−101	−87	−75	−64	−37
Total Stockholders Equity	6	2	5	7	25
Total Liabilities and Stockholders Equity	8	3	6	9	26

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	1,204	782	222	—	484
Non-cash lease expense for right-of-use assets	70,677	87,184	81,530	—	—
Stock-based compensation	857,550	629,514	1	9	3
Prepaid expenses and other	834,651	−1	956,834	210,549	−1
Operating lease liability	−66,905	−83,649	−78,896	−87,937	−87,200
Accounts payable	175,916	569,263	−15,931	108,643	−101,789
Due from related parties	—	−39	−12	—	—
Accrued expenses	600,726	432,457	−256,787	243,796	−65,049
Net cash used in operating activities	−11	−11	−8	−10	−9
Purchase of digital asset	−850,000	—	—	—	—
Purchase of equipment	—	−3,244	—	—	—
Net cash used in investing activities	−850,000	−3,244	−2,776	—	—
Net proceeds from issuance of common stock	17	8	6	—	10
Shares withheld to pay taxes on stock-based compensation	−10,404	−15,902	—	−88,843	−64,396
Settlement of stock award	—	−8,561	−52,746	—	—
Payment of finance lease obligation	−6,602	−5,202	—	—	—
Net cash provided by financing activities	17	8	6	−388,843	10
Net Increase (Decrease) in Cash and Cash Equivalents	4	−4	−2	−10	1
Cash paid for interest	5,607	1,204	—	—	—
Cash paid for income taxes	—	—	—	—	—
Issuance of 200 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor	—	189,000	—	400,000	400,000
Right-of-use asset obtained in exchange for financing lease liability	—	11,804	—	—	—
Financing lease liability	—	−11,804	—	—	—
Net	—	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro